GeneOne Life Science, Inc. (KRX:011000)

Market Cap	231.25B
Revenue (ttm)	37.19B
Net Income (ttm)	-47.89B
Shares Out	84.71M
EPS (ttm)	-600.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,120,453
Average Volume	6,767,948
Open	2,980.00
Previous Close	3,015.00
Day's Range	2,705.00 - 3,015.00
52-Week Range	1,830.00 - 4,735.00
Beta	0.93
RSI	47.98
Earnings Date	May 14, 2025

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1976
• Employees: 42
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 011000

Financial Performance

In 2024, GeneOne Life Science's revenue was 35.72 billion, a decrease of -11.15% compared to the previous year's 40.20 billion. Losses were -48.54 billion, -37.59% less than in 2023.